Romiplostim (Nplate)
Overview
A thrombopoietin (TPO) receptor agonist consisting of a peptide sequence that binds the TPO receptor (c-Mpl) fused to an IgG1 Fc domain (peptibody). Romiplostim activates JAK2/STAT5 signaling in megakaryocyte progenitors, promoting megakaryocyte proliferation, differentiation, and platelet production.
Mechanism of Action
It has no sequence homology to endogenous TPO, minimizing the risk of cross-reactive antibody formation.
Research Summary & Key Findings
FDA-approved in 2008 for chronic immune thrombocytopenia (ITP) in adults with insufficient response to corticosteroids, immunoglobulins, or splenectomy. Clinical trials showed durable platelet responses in 79-88% of patients with splenectomized and non-splenectomized ITP. Extended treatment studies demonstrated sustained platelet response for up to 5 years. Risk of bone marrow reticulin fiber deposition requires monitoring.
Clinical Status
Romiplostim (Nplate) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "Romiplostim"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Romiplostim"
Registered interventional and observational studies, including status and phase.
- PubChem — "Romiplostim"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Hematology
Bivalirudin (Angiomax)
FDA ApprovedA synthetic 20-amino acid peptide that acts as a direct thrombin inhibitor by binding both the catalytic active site and...
View detailsPegcetacoplan (Empaveli)
FDA ApprovedA pegylated cyclic peptide that inhibits complement component C3, the central node of all three complement activation pa...
View detailsPeginesatide (Omontys)
FDA ApprovedPeginesatide is a synthetic pegylated peptide-based erythropoiesis-stimulating agent (ESA) consisting of two 21-amino ac...
View detailsEltrombopag Peptide Mimetics
FDA ApprovedEltrombopag is a small-molecule, non-peptide thrombopoietin receptor agonist that binds to the transmembrane domain of t...
View detailsStart Your Consultation
Get an AI-proposed Romiplostim (Nplate) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Romiplostim (Nplate).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.